Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids

European Respiratory Journal

Volumn 50, Issue 2, 2017, Pages

  Bateman, Eric D ^a   Guerreros, Alfredo G ^b   Brockhaus, Florian ^c   Holzhauer, Björn ^c   Pethe, Abhijit ^c   Kay, Richard A ^c   Townley, Robert G ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Clinica Internacional   (Peru)

^c NOVARTIS PHARMA AG   (Switzerland)

^d CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FEVIPIPRANT; MONTELUKAST; PLACEBO; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN RECEPTOR; INDOLEACETIC ACID DERIVATIVE; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; INFLUENZA; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHARYNGITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; ASTHMA; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG MONITORING; MIDDLE AGED; PROCEDURES; RESPIRATION CONTROL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACETATES; ADULT; AIRWAY MANAGEMENT; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG MONITORING; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; INDOLEACETIC ACIDS; MALE; MIDDLE AGED; PYRIDINES; QUINOLINES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85037724125     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00670-2017     Document Type: Article

References (19)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2015. Date last accessed: March 31, 2016. www.ginasthma.org
2. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014; 24: 14009.
3. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? Am J Respir Crit Care Med 2004; 170: 836-844.
4. Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy 2009; 39: 193-202.
5. Barranco P, Pérez-Francés C, Quirce S, et al. Consensus document on the diagnosis of severe uncontrolled asthma. J Investig Allergol Clin Immunol 2012; 22: 460-475.
6. Accordini S, Corsico A, Cerveri I, et al. The socio-economic burden of asthma is substantial in Europe. Allergy 2008; 63: 116-124.
7. Juniper EF, Wisniewski ME, Cox FM, et al. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004; 23: 287-291.
8. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics 2005; 61: 738-748.
9. Pinheiro J, Bornkamp B, Glimm E, et al. Model-based dose finding under model uncertainty using general parametric models. Stat Med 2014; 33: 1646-1661.
10. Schorning K, Bornkamp B, Bretz F, et al. Model selection versus model averaging in dose finding studies. Stat Med 2016; 35: 4021-4040.
11. Erpenbeck VJ, Popov TA, Miller D, et al. The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma. Pulm Pharmacol Ther 2016; 39: 54-63.
12. Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2016; 4: 699-707.
13. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999; 160: 1862-1868.
14. Paggiaro P, Halpin DMG, Buhl R, et al. P260 Tiotropium Respimat® add-on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: results from a phase III trial. Thorax 2014; 69: Suppl 2, A191.
15. Hall IP, Fowler AV, Gupta A, et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther 2015; 32: 37-44.
16. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003; 327: 891.
17. Korn D, Van den Brande P, Potvin E, et al. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr Med Res Opin 2009; 25: 489-497.
18. Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2016; 4: 699-707.
19. Krug N, Gupta A, Badorrek P, et al. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2014; 133: 414-419.